BREAST CANCER

流行病学和癌症控制项目由来自12个部门的34名研究人员（30名正式成员和4名准成员）组成。该方案的总体使命是降低癌症发生和死亡的风险，提高癌症幸存者的生活质量。为了完成这一使命，它有4个主要的科学目标：1）确定癌症的环境和遗传决定因素，以改善癌症预防的手段，特别关注了解环境因素在癌症病因中的作用，确定癌症病因中的代谢和生殖因素，了解人类遗传学在癌症病因和进展中的作用，2）通过改变风险因素来减少癌症负担，特别关注肥胖控制和减少烟草使用; 3）通过早期发现癌症来减少癌症负担，特别注重应用方法，增加服务不足人群的筛查参与率，并开发新的早期检测生物标志物;（4）解决癌症患者和幸存者的负担问题，特别注重满足服务不足者的需要。研究重点领域是跨学科的，包括来自ECC和其他纽约大学癌症研究所研究项目的人口，实验室和临床科学家。Richard Hayes博士和Brian施密特博士是该项目的共同负责人。这是一个新的方案，目前有16，940，943美元的资金。这一时期的出版物共计216种，其中17.6%是方案内的，11.1%是方案间的，8.8%是方案内和方案间的合作。相关性（参见说明）：流行病学和癌症控制计划进行癌症流行病学研究，并评估癌症预防和外展工作，从而有助于在不同的纽约地区人口和更广泛的有效的癌症负担减轻计划的证据基础。项目总结（见说明）：乳腺癌项目由来自17个部门的38名研究人员（32名正式成员和6名准成员）组成。该方案旨在将文化差异和基于人口的研究与基于实验室的基础、转化和临床研究方案相结合，通过对乳腺癌的协同理解和创新治疗方法，改变乳腺癌死亡率的状况。为此，他们制定了以下具体目标：1）了解阻碍诊断和护理并导致治疗和生存差异的文化和经济因素; 2）了解有助于乳腺癌发展、侵袭、复发和转移的免疫学、微环境、遗传和分子机制; 3）将乳腺癌发展和进展的科学发现转化为创新的治疗方法和治疗方法，通过改善诊断和治疗使患者受益;和4）促进临床医生和研究科学家的发展，共同努力建立新的基础，转化和临床研究领域。为了实现这些目标，正在开发六个主要领域：1）激素信号; 2）侵袭性，转移和血管生成; 3）免疫/免疫干预和与乳腺癌的关联; 4）流行病学; 5）乳腺癌的放射生物学和物理学研究;以及6）社会文化和社区研究和计划。Silvia Formenti博士和Robert Schneider博士是该项目的联合负责人。自上次竞争性申请以来，供资总额从9 789 777美元增加到11 595 777美元。成员从44个减少到38个。这一期间的出版物共计275份，其中16.7%是方案内出版物，16%是方案间出版物，8.7%是方案内和方案间合作出版物。

PROJECT SUMMARY (See instructions); The Epidemiology & Cancer Control Program is composed of 34 investigators (30 Full and 4 Associate members) from 12 Departments. The overall mission of the Program is to reduce the risk of cancer occurrence and death and to enhance the quality of life of cancer survivors. To fulfill this mission, it has 4 major scientific objectives: 1) To identify environmental and genetic determinants of cancer to improve means of cancer prevention, focusing specifically on understanding the role of environmental factors in cancer etiology, determining the metabolic and reproductive factors in cancer etiology, understanding the role of human genetics in cancer etiology and progression, and identifying cancer risks associated with the human microbiome; 2) To reduce cancer burden by risk factor modification, with a specific focus on obesity control and tobacco use reduction; 3) To reduce cancer burden by early detection of cancer, with a specific focus on the application of methods to increase screening participation by underserved populations and the development of novel early detection biomarkers; and 4) To address cancer-related burden in patients and survivors, with a particular emphasis on meeting the needs of the underserved. The research focus areas are interdisciplinary, including population, laboratory and clinical scientists from ECC and other NYU Cancer Institute Research Programs. Drs. Richard Hayes and Brian Schmidt are the Co-Leaders for this Program. This is a new Program that currently has $16,940,943 on funding. Publications for the period total 216, of which 17.6% are intra-programmatic, 11.1% are inter-programmatic, and 8.8% are both intra- and interprogrammatic collaborations. RELEVANCE (See instructions): The Epidemiology and Cancer Control Program undertakes epidemiological research on cancer and evaluates cancer prevention and outreach efforts, thus contributing to the evidence-base for effective cancer burden reduction programs in the diverse New York regional population and more broadly. PROJECT SUMMARY (See instructions): The Breast Cancer Program is composed of 38 investigators (32 Full and 6 Associate members) from 17 Departments. The Program aims to integrate so do-cultural disparities and population-based research with laboratory-based basic, translational and clinical research programs that can change the state of breast cancer mortality through a synergistic understanding of breast cancer and innovative approaches in treatment. To do so, they have developed the following Specific Aims: 1) Understand the so do-cultural and economic factors that impede diagnosis and care and contribute to disparities in treatment and survival; 2) Understand the immunological, micro-environmental, genetic and molecular mechanisms that contribute to the development, invasion, recurrence and metastasis of breast cancer; 3) Translate scientific findings to breast cancer development and progression into innovative therapeutics and therapeutic approaches to benefit patients by improving diagnosis and treatment; and 4) Advance the development of clinicians and research scientists working collaboratively to establish novel basic, translational and clinical research areas. To address these aims, six major areas are being developed: 1) Hormonal signaling; 2) Invasiveness, metastasis and angiogenesis; 3) Immunity/immunological intervention and association with breast cancer; 4) Epidemiology; 5) Radiobiology and physics research in breast cancer; and 6) Socio-cultural and community based research and programs. Drs. Silvia Formenti and Robert Schneider are the Co-Leaders for this Program. Total funding increased from $9,789,777 to $11,595,777 since the last competitive application. Membership has decreased from 44 to 38. Publications for the period total 275, of which 16.7% are intraprogrammatic, 16% are inter-programmatic, and 8.7% are both intra- and inter-programmatic collaborations.